C. Harrison, Essential thrombocythaemia: challenges and evidence-based management, British Journal of Haematology, vol.22, issue.1, pp.153-165, 2005.
DOI : 10.1034/j.1600-0609.2000.90235.x

T. Barbui, G. Barosi, and A. Grossi, Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation, Haematologica. Feb, vol.89, issue.2, pp.215-247, 2004.

F. Palandri, L. Catani, and N. Testoni, Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy, American Journal of Hematology, vol.53, issue.4 Part 2, 2009.
DOI : 10.1002/ajh.21360

F. Passamonti, E. Rumi, and L. Arcaini, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-51, 2008.
DOI : 10.3324/haematol.13346

A. Tefferi and M. Elliott, Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost, 2007.

A. Vannucchi, E. Antonioli, and P. Guglielmelli, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, pp.840-846, 2007.

D. Stefano, V. Za, T. Rossi, and E. , Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia, American Journal of Hematology, vol.94
DOI : 10.1002/ajh.21593

F. Lussana, S. Caberlon, and C. Pagani, Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review, Thrombosis Research, vol.124, issue.4, pp.409-426, 2009.
DOI : 10.1016/j.thromres.2009.02.004

M. Marchetti and A. Falanga, Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders, Pathophysiol Haemost Thromb, vol.36, pp.3-4148, 2008.

A. Tefferi, N. Gangat, and A. Wolanskyj, The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood, p.4105, 2007.

F. Passamonti, E. Rumi, and L. Arcaini, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-51, 2008.
DOI : 10.3324/haematol.13346

F. Girodon, F. Dutrillaux, and J. Broséus, Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients, Leukemia, vol.24, issue.4, pp.900-903, 2010.
DOI : 10.4065/81.2.159

A. Carobbio, G. Finazzi, and V. Guerini, Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status, Blood, vol.109, issue.6, pp.2310-2313, 2007.
DOI : 10.1182/blood-2006-09-046342

A. Carobbio, E. Antonioli, and P. Guglielmelli, Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia, Journal of Clinical Oncology, vol.26, issue.16, pp.2732-2738, 2008.
DOI : 10.1200/JCO.2007.15.3569

A. Wolanskyj, S. Schwager, and R. Mcclure, Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors, Mayo Clinic Proceedings, vol.81, issue.2
DOI : 10.4065/81.2.159

S. Murphy, P. Peterson, and H. Iland, Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment, Semin Hematol, vol.34, issue.1, pp.29-39, 1997.

J. Vardiman, N. Harris, and R. Brunning, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-302, 2002.
DOI : 10.1182/blood-2002-04-1199

J. Bennett, D. Catovsky, and M. Daniel, Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia, Annals of Internal Medicine, vol.103, issue.4, pp.620-625, 1985.
DOI : 10.7326/0003-4819-103-4-620

G. Barosi, A. Ambrosetti, and C. Finelli, The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia, British Journal of Haematology, vol.1, issue.4, 1999.
DOI : 10.1016/0145-2126(96)00028-8

H. Quentmeier, R. Macleod, and M. Zaborski, JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia, pp.471-477, 2006.

F. Passamonti, E. Rumi, C. Pascutto, M. Cazzola, and M. Lazzarino, Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia, Journal of Thrombosis and Haemostasis, vol.22, issue.9, pp.1587-1596, 2009.
DOI : 10.1111/j.1538-7836.2009.03531.x

N. Gangat, A. Wolanskyj, and R. Mcclure, Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients, Leukemia, vol.100, issue.2, pp.270-276, 2007.
DOI : 10.1038/sj.leu.2404500

A. Tefferi and J. Vardiman, Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, vol.5, issue.1, pp.14-22, 2008.
DOI : 10.1038/sj.leu.2404955